Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program

CIGB-247 is a cancer therapeutic vaccine that uses as antigen a variant of human vascular endothelial growth factor (VEGF) mixed with the bacterially-derived adjuvant VSSP. CIGB-247 has been already evaluated ...

Source: BMC Immunology - March 14, 2020 Category: Allergy & Immunology Authors: Javier S ánchez Ramírez, Yanelys Morera Díaz, Mónica Bequet-Romero, Francisco Hernández-Bernal, Yenima Martín Bauta, Katty-Hind Selman-Housein Bernal, Ana Victoria de la Torre Santos, Mariela Pérez de la Iglesia, Lian Trimiño Lorenzo and Marta Aya Tags: Research article Source Type: research